India, June 13 -- Genmab A/S (GMAB) reported positive findings from two clinical studies evaluating epcoritamab in elderly patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) who are not eligible for anthracycline-based chemotherapy.
In the Phase 2 EPCORE DLBCL-3 trial, fixed-duration epcoritamab monotherapy demonstrated encouraging efficacy. The study showed an overall response rate (ORR) of 67% and a complete response (CR) rate of 58%. The safety profile was consistent with expectations in this patient group, with cytokine release syndrome (CRS) occurring in 71% of patients-most frequently during Cycle 1-and immune effector cell-associated neurotoxicity syndrome (ICANS) reported in 18%.
The Phase 1b/2 EPCORE NHL-2 trial ...